van Wezel Tom, Lombaerts Marcel, van Roon Eddy H, Philippo Katja, Baelde Hans J, Szuhai Karoly, Cornelisse Cees J, Cleton-Jansen Anne-Marie
Department of Pathology, Leiden University Medical Center, Albiniusdreef 2, 2333ZA Leiden, The Netherlands.
Breast Cancer Res. 2005;7(6):R998-1004. doi: 10.1186/bcr1337. Epub 2005 Oct 18.
Chromosome arm 16q is the second most frequent target of loss of heterozygosity in breast cancer and is, therefore, a candidate to contain one or more classic tumour suppressor genes (TSGs). E-cadherin at 16q22 was identified as a TSG in lobular breast cancer, but TSGs in ductal breast cancer remain elusive. Several genes have been suggested as potential candidates (e.g. CBFA2T3, CTCF and WWOX) but no inactivating mutations could be identified in these genes and they thus fail to fit the classic two-hit model for a TSG. With the completion of the human transcriptome, new candidate genes can be distinguished. Besides mutational inactivation, a TSG could, at least in a subset of the tumours, be transcriptionally suppressed or even inactivated. Studying candidate genes for expression and somatic mutations could thus identify the TSGs.
Possible candidates CBFA2T3, TERF2 and TERF2IP, FBXL8 and LRRC29 and FANCA were studied for insertion and deletion mutations and for expression differences using quantitative RT-PCR in a panel of tumour cell lines and primary tumours with and without loss of 16q.
None of the genes showed mutations or obvious expression differences. FANCA expression increased with tumour grade.
Apparently, the underlying genetics at chromosome 16q are complex or the TSGs remain to be identified. Multiple mechanisms, such as mutations, promoter hypermethylation or haploinsufficiency, might lead to the inactivation of a TSG.
16号染色体长臂是乳腺癌中杂合性缺失第二常见的靶点,因此,它是一个可能包含一个或多个经典肿瘤抑制基因(TSG)的候选区域。位于16q22的E-钙黏蛋白在小叶乳腺癌中被鉴定为肿瘤抑制基因,但导管乳腺癌中的肿瘤抑制基因仍不明确。已有几个基因被认为是潜在的候选基因(如CBFA2T3、CTCF和WWOX),但在这些基因中未发现失活突变,因此它们不符合经典的肿瘤抑制基因双打击模型。随着人类转录组的完成,可以区分出新的候选基因。除了突变失活外,肿瘤抑制基因至少在一部分肿瘤中可能会被转录抑制甚至失活。因此,研究候选基因的表达和体细胞突变可以鉴定出肿瘤抑制基因。
使用定量逆转录聚合酶链反应(qRT-PCR),在一组有或无16q缺失的肿瘤细胞系和原发性肿瘤中,研究了可能的候选基因CBFA2T3、TERF2和TERF2IP、FBXL8和LRRC29以及FANCA的插入和缺失突变以及表达差异。
这些基因均未显示出突变或明显的表达差异。FANCA的表达随肿瘤分级增加而升高。
显然,16号染色体上的潜在遗传学机制很复杂,或者肿瘤抑制基因仍有待鉴定。多种机制,如突变、启动子高甲基化或单倍体不足,可能导致肿瘤抑制基因失活。